Prabhakar Myadaraveni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prabhakar Myadaraveni has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Mamatha Kasula
Department of Chemistry, Kakatiya University, Warangal 506009, Telangana, India
2 shared publications - Rambabu Palabindela
Department of Chemistry (H and S), School of Engineering and Technology, Guru Nanak Institutions Technical Campus, Hyderabad, 501 506, Telangana, India
2 shared publications Devendar Banothu
Department of Chemistry, Kakatiya University, Warangal-506009, India
1 shared publication- Rajshekhar A. Kore
Department of Medicine, Cardiology Division, University of Arkansas for Medical Sciences, Little Rock, AR and the Central Arkansas Veterans Healthcare System, Little Rock, USA
1 shared publication - Ramakrishna Bodapati
Sri Vasavi Engn Coll, Peda Tadepalli 534101, Andhra Pradesh, India
1 shared publication - Ramesh Gondru
Department of Chemistry, National Institute of Technology, Warangal, India
1 shared publication
Latest Publications
- Open Access
- 29 March 2025
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 37 (4) , 893-908
N-Alkylation Hybrids: Synthesis, Characterization, Anticancer Properties and Computational Insights
A series of (E)-2-(2-(anthracen-9-ylmethylene)hydrazinyl)-4-(pyrrolidin-1-ylmethyl)thiazole (7a-l) were synthesized and evaluated for their in vitro anticancer activity against three human cancer cell lines of MCF-7 (breast), A549 (lung) and HepG2 (liver). In this study, cisplatin served as the positive control. The results showed that the synthesized compounds 7c, 7g, 7i, 7j and 7l demonstrated promising activity against all three cancer cell lines. Notably, compound 7j exhibited higher activity than the standard drug cisplatin against MCF-7, A549 and HepG2, with IC50 values of 9.08 ± 0.32 µM, 5.92 ± 1.16 µM and 6.96 ± 0.13 µM, respectively. Molecular docking studies of the compounds 7g, 7i and 7j with DNA topoisomerase II (PDB ID:3QX3) indicated strong affinity toward the target protein. Moreover, an in silico pharmacokinetic profile was generated for compounds 7g, 7i and 7j using SWISS/ADMET and pkCSM. Furthermore, compounds 7g, 7i and 7j were found to comply with the Lipinski, Ghose, Veber, Egan and Muegge rules. Based on the results, compound 7j was characterized by and density functional theory (DFT) studies.
- 29 March 2025
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 37 (4) , 893-908
Open AccessN-Alkylation Hybrids: Synthesis, Characterization, Anticancer Properties and Computational Insights
A series of (E)-2-(2-(anthracen-9-ylmethylene)hydrazinyl)-4-(pyrrolidin-1-ylmethyl)thiazole (7a-l) were synthesized and evaluated for their in vitro anticancer activity against three human cancer cell lines of MCF-7 (breast), A549 (lung) and HepG2 (liver). In this study, cisplatin served as the positive control. The results showed that the synthesized compounds 7c, 7g, 7i, 7j and 7l demonstrated promising activity against all three cancer cell lines. Notably, compound 7j exhibited higher activity than the standard drug cisplatin against MCF-7, A549 and HepG2, with IC50 values of 9.08 ± 0.32 µM, 5.92 ± 1.16 µM and 6.96 ± 0.13 µM, respectively. Molecular docking studies of the compounds 7g, 7i and 7j with DNA topoisomerase II (PDB ID:3QX3) indicated strong affinity toward the target protein. Moreover, an in silico pharmacokinetic profile was generated for compounds 7g, 7i and 7j using SWISS/ADMET and pkCSM. Furthermore, compounds 7g, 7i and 7j were found to comply with the Lipinski, Ghose, Veber, Egan and Muegge rules. Based on the results, compound 7j was characterized by and density functional theory (DFT) studies.